Abbott Laboratories stock reports 4.8 percent Q2 sales growth
Alpha Vantage · AD HOC NEWS · · AI-summarised by FinFlash
Abbott Laboratories reported 4.8% comparable sales growth in Q2 2026, with adjusted EPS reaching USD 1.31, surpassing guidance. The company raised its full-year adjusted EPS guidance and is scheduled to report Q3 2026 results on October 21, 2026. Analysts have a consensus "Moderate Buy" rating with an average 12-month target price significantly above the current trading price.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.